Enzymatica AB (SE:ENZY)

:ENZY

ENZY

Enzymatica AB

RESEARCH TOOLSreports

Want to see SE:ENZY full AI Analyst Report?

Enzymatica AB (ENZY) Price & Analysis

0 Followers

ENZY Stock Chart & Stats

kr2.00

-kr0.34(-10.43%)

At close: Mar 06 4:00 PM EST

kr2.00

-kr0.34(-10.43%)

Day’s Range― - ―

52-Week Rangekr1.60 - kr3.40

Previous CloseN/A

Volume634.97K

Average Volume (3M)93.66K

Market Cap

kr631.11M

Enterprise Valuekr583.87M

Total Cash (Recent Filing)kr26.06M

Total Debt (Recent Filing)kr661.00K

Price to Earnings (P/E)―

Beta0.32

Next Earnings

Jul 16, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.20

Shares Outstanding242,735,100

10 Day Avg. Volume44,136

30 Day Avg. Volume93,658

Financial Highlights & Ratios

PEG Ratio0.36

Price to Book (P/B)3.71

Price to Sales (P/S)8.56

P/FCF Ratio-11.19

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.3

Revenue Forecast (FY)kr109.00M

Bulls Say, Bears Say

Bulls Say

Low LeverageVery low debt reduces refinancing and solvency risk, giving management flexibility to fund operations, pursue partnerships or raise capital on better terms. A conservative balance sheet is a durable structural strength while the company works to restore profitability.

Healthy Gross MarginA ~61% gross margin provides structural cushion versus input cost swings and partner economics. If revenue stabilizes, these margins can support faster operating leverage and internal reinvestment into marketing or product development without immediate reliance on external funding.

Scalable Commercial ModelCombination of direct sales and partner licensing diversifies revenue streams and lowers single-market risk. Partner-based distribution enables scalable geographic expansion and recurring supply/royalty income without the full cost of local commercial setups.

Bears Say

Persistent LossesExtremely negative net margins have persisted, eroding equity and limiting retained earnings. Sustained unprofitability increases execution risk, constrains reinvestment capacity, and forces management to pursue either structural cost reductions, volume growth, or potentially dilutive financing.

Negative Cash GenerationMaterial operating and free cash flow deficits indicate ongoing cash burn and a structural funding need. Continued negative cash generation pressures liquidity, increases reliance on external capital or partner funding, and constrains investments required to scale commercial efforts sustainably.

Revenue StagnationFlat trailing revenue with weakening growth momentum suggests limited organic adoption beyond current markets and seasonality dependence. Stagnant top-line hampers the ability to spread fixed costs, delays margin recovery, and makes the business more reliant on partnerships or new products to drive durable growth.

ENZY FAQ

What was Enzymatica AB’s price range in the past 12 months?

Enzymatica AB lowest stock price was kr1.60 and its highest was kr3.40 in the past 12 months.

What is Enzymatica AB’s market cap?

Enzymatica AB’s market cap is kr631.11M.

When is Enzymatica AB’s upcoming earnings report date?

Enzymatica AB’s upcoming earnings report date is Jul 16, 2026 which is in 28 days.

How were Enzymatica AB’s earnings last quarter?

Enzymatica AB released its earnings results on Apr 28, 2026. The company reported -kr0.055 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.055.

Is Enzymatica AB overvalued?

According to Wall Street analysts Enzymatica AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Enzymatica AB pay dividends?

Enzymatica AB does not currently pay dividends.

What is Enzymatica AB’s EPS estimate?

Enzymatica AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Enzymatica AB have?

Enzymatica AB has 242,735,100 shares outstanding.

What happened to Enzymatica AB’s price movement after its last earnings report?

Enzymatica AB reported an EPS of -kr0.055 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.124%.

Which hedge fund is a major shareholder of Enzymatica AB?

Currently, no hedge funds are holding shares in SE:ENZY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Enzymatica AB

Enzymatica AB, a life science company headquartered in Lund, Sweden, focuses on the development and sale of medical devices for infection-related illnesses. Founded in 2007, its primary offering is the ColdZyme mouth spray, designed to help prevent and reduce the duration of the common cold. The company also produces various enzyme formulations. This mouth spray is distributed across several European markets under different brand names: ViruProtect in Denmark, STADAProtect in Germany, Psysiomer Stop Virus in France, and Zerinol Virus Defense in Italy.